Navigation Links
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
Date:8/19/2007

PALO ALTO, Calif., Aug. 15 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that new guidelines, developed jointly by the American College of Cardiology Foundation and the American Heart Association and published in this week's issue of Circulation, state that, "ranolazine may be safely administered for symptom relief after UA/NSTEMI."

Ranexa(R) (ranolazine extended-release tablets) is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates. The product has not been determined by regulatory authorities to be safe and effective for any other use.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to treatment guidelines, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. siRNA Design Guidelines
2. Federal and global guidelines on stem cell research offer a level playing field
3. With ethics guidelines, political consensus emerging on stem-cell research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2016)... ... ... Ryan Benton was diagnosed with Duchenne Muscular Dystrophy (DMD) at the age of ... is a relatively common progressive genetic disorder, which causes aggressive deterioration of the muscles. ... met with the founder of the Stem Cell Institute in Panama City, ...
(Date:5/17/2016)... ... May 17, 2016 , ... ResearchDx, the premier ... based in Saudi Arabia, have formed a partnership to bring their expertise in ... Kingdom of Saudi Arabia (KSA). , The partnership addresses the specific needs ...
(Date:5/17/2016)... , May 17, 2016 ... in Basel, Switzerland announced ... inhibitor of P38 mitogen-activated protein kinase. ... Strekin will build the necessary research foundation ... in which MAP Kinases play fundamental roles. Pamapimod ...
(Date:5/17/2016)... ... May 17, 2016 , ... HOLLOWAY AMERICA, a stainless steel ... Chapter’s Tech Ed Day on Thursday, May 19 in St. Louis, Missouri. The event ... AMERICA will participate in a vendor showcase during the early afternoon of the event, ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):